We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Orchestra BioMed Holdings Inc (OBIO) USD0.0001

Sell:$6.11 Buy:$9.00 Change: $0.36 (5.94%)
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
Sell:$6.11
Buy:$9.00
Change: $0.36 (5.94%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
Sell:$6.11
Buy:$9.00
Change: $0.36 (5.94%)
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Orchestra BioMed Holdings, Inc. is a biomedical innovation company. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. It is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. It is developing bioelectronic therapies based on patented CNT technology. BackBeat CNT, also known as Atrioventricular Interval Modulation (AVIM) therapy, is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

Contact details

Address:
150 Union Square Drive
NEW HOPE
18938
United States
Telephone:
+1 (646) 3439298

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
OBIO
ISIN:
US68572M1062
Market cap:
$209.55 million
Shares in issue:
37.82 million
Sector:
Health Care Equipment
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • David Hochman
    Chairman of the Board, Chief Executive Officer
  • Darren Sherman
    President, Chief Operating Officer, Director
  • Andrew Taylor
    Chief Financial Officer
  • Bill Little
    Executive Vice President - Corporate Development and Strategy
  • George Papandreou
    General Manager and Senior Vice President - Focal Therapies
  • Yuval Mika
    General Manager and Chief Technology Officer - Bioelectronic Therapies

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.